Stock PVCT PROVECTUS BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Delayed OTC Markets
Other stock markets
 20:53:07 28/06/2024 BST 		5-day change 1st Jan Change
0.1299 USD -3.78% Intraday chart for Provectus Biopharmaceuticals, Inc. -17.16% +35.31%
05-21 Provectus Biopharmaceuticals, Inc. Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting CI
05-14 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Provectus Biopharmaceuticals, Inc. Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose
Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President
Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer
Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Provectus Biopharmaceuticals, Inc. Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
Provectus Biopharmaceuticals, Inc. Announces Management Changes
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Advanced Cutaneous Melanoma
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Metastatic Uveal Melanoma
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10(R) and Keytruda(R) for First-Line Stage III Melanoma at Melanoma Bridge 2022
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Provectus Biopharmaceuticals Inc. Establishes Research Collaboration with University of Texas Medical Branch At Galveston
Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PVCT Stock
  4. News Provectus Biopharmaceuticals, Inc.
  5. Other languages